Product injury firm Hissey Kientz LLP has recently established a practice area page for the psoriasis treatment drug Raptiva (efalizumab). The once-a-week injection has been used to treat more than 46,000 patients with chronic plaque psoriasis since 2003.
In October 2008, the FDA forced Raptiva’s manufacturer to add a black box warning to the drug package, after at least four fatal cases of progressive multifocal leukoencephalopathy (PML) had been identified among patients who were treated with Raptiva. Genentech, the drug’s manufacturer, is voluntarily withdrawing Raptiva from US markets by June 8, 2009.
For news, the history and adverse effects of Raptiva, and more details on the FDA’s warning, visit the Hissey Kientz Raptiva practice page.